This week, we speak with Joe Reece and Stephen Kadenacy, from the SilverBox team. Joe and Stephen led the Boxwood Merger Corp. and SilverBox Engaged Merger Corp. I transactions, as well as recently priced the SilverBox Corp. III IPO.
We dig into their perspective, having priced SPACs in three very different market environments. Joe and Steve explain why and how they maintained their value priorities while IPOing their third SPAC in the difficult market of early 2023.
The pair also discuss the relative of advantages of having committed capital from forward purchase agreements at IPO versus the flexibility of diverse potential PIPE investors down the road.
What will the landscape look like once the SPAC cycle fully resets, and what does it take for a sponsor to bank a successful deal while the current macro conditions exist?
Give it a listen.
At the SPAC of Dawn The final two trading days of the year are not to be absent of action with three SPACs scheduled extension votes today and surely more unscheduled business will be tucked into the final hours of 2024. One loose end that is now being tied up is the role of Cantor...
At the SPAC of Dawn While futures indicate the Santa rally may be retreating back to the North Pole, de-SPACs have nonetheless notched a solid week and SPACs still in other points in their processes still have plenty of business left on their plate. Three SPACs are asking shareholders for extensions today while two more...
SPACInsider 2024 Awards 2024 was clearly a rebuilding year for SPACs and the pace didn’t really gather momentum until June. But in typical SPAC fashion, once the market catches fire, it builds very, very quickly. With that being said, there are some noteworthy standouts this year that are worth highlighting. As such, this is the...
At the SPAC of Dawn (UPDATED) It was a slow start to the day after the Christmas holiday, especially because the SEC was “experiencing technical difficulties” this morning. That makes for a slow news day. Other than that, we hope everyone had a great holiday and is easing back into the work flow. Deals and...
Aimei Health Technology II Co., Ltd (NASDAQ:AHJKU) has filed for a $60 million SPAC ostensibly to pair up with a small cap biotech or medical device target, but its team’s experience both in SPACs and beyond suggest the vehicle will be open to a broad set of potential targets. It is the first SPAC to...